---
title: "Sanofi Completes Acquisition of Dynavax Technologies"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275471636.md"
datetime: "2026-02-10T14:01:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275471636.md)
  - [en](https://longbridge.com/en/news/275471636.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275471636.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275471636.md) | [English](https://longbridge.com/en/news/275471636.md)


# Sanofi Completes Acquisition of Dynavax Technologies

Sanofi has completed its acquisition of Dynavax Technologies Corporation, bringing the adult hepatitis B vaccine HEPLISAV-B and several vaccine pipeline projects, including a shingles vaccine candidate currently in phase 1⁄2 studies, into its portfolio. Dynavax will now operate as an indirect, wholly owned subsidiary of Sanofi, and its common stock will no longer be traded on the NASDAQ. This move expands Sanofi’s presence in adult immunization by combining Dynavax’s differentiated vaccines with Sanofi’s commercial reach and development capabilities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163976-en) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Sanofi (SNY.US)](https://longbridge.com/zh-HK/quote/SNY.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Dynavax Tech (DVAX.US)](https://longbridge.com/zh-HK/quote/DVAX.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)

## 相關資訊與研究

- [Sanofi Wins Japan Orphan Status for Rilzabrutinib and Moves to Strengthen Governance](https://longbridge.com/zh-HK/news/278578865.md)
- [Brazil's EMS purchases Sanofi's Medley](https://longbridge.com/zh-HK/news/278113014.md)
- [How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors](https://longbridge.com/zh-HK/news/278666481.md)
- [BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment](https://longbridge.com/zh-HK/news/278372828.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/zh-HK/news/278778570.md)